7.5-Year Follow-Up Affirms Nivolumab’s Superiority Over Ipilimumab in Advanced Melanoma
Nivolumab, whether in combination with ipilimumab or as a monotherapy, was associated with improved overall survival, progression-free survival, and melanoma-specific survival, compared with ipilimumab in advanced melanoma.
Early Treatment for Hot-Flashes Is Prognostic of Worse Outcomes for Hormonal Therapy in Patients with ER+ Breast Cancer
Patients with breast cancer who experience adjuvant hormone therapy (AHT)-related hot flashes and are treated for hot flashes at the beginning of therapy had worse outcomes than those who did not.
Adding Durvalumab to Chemotherapy Continues to Improve Overall Survival in Advanced Biliary Tract Cancer
A subgroup analysis found that the addition of durvalumab to chemotherapy resulted in maintained overall survival benefit in patients with advanced biliary tract cancer, regardless of primary tumor location.
Galinsky Breaks Down Venetoclax Symptom Management in AML
Ilene Galinsky, BSN, MSN, ANP-C, underscores effective symptom management strategies when prescribing venetoclax to patients with acute myeloid leukemia.
How To Respond When a Patient on Chemotherapy Presents With Pulmonary Embolism
Laura J. Zitella, MS, RN, ACNP-BC, AOCN, presents a case study of a patient receiving chemotherapy for osteosarcoma who begins experiencing shortness of breath.
Galinsky Clarifies Best Practices With Venetoclax in the AML Setting
Ilene Galinsky, BSN, MSN, ANP-C, discusses the evolution of targeted therapy in acute myeloid leukemia treatment, and how venetoclax plays into the treatment paradigm.
Updated NCCN Guidelines Recommend Trastuzumab Deruxtecan, Sacituzumab Govitecan for Advanced Breast Cancer
The NCCN guidelines have been amended to include trastuzumab deruxtecan for use in patients with HER2-low metastatic breast cancer and sacituzumab govitecan for use in patients with triple-negative breast cancer or hormone receptor–positive, HER2-negative disease.
Addition of HER2-Vaxx Vaccine to Standard Chemotherapy Prolongs Overall Survival in HER2+, Advanced Gastric/GEJ Cancer
The addition of the HER2-Vaxx vaccine to chemotherapy resulted in 41.5% reduction in the risk of death compared with chemotherapy alone among patients with gastric cancers.
Venetoclax/Obinutuzumab Continues to Show Efficacy in Unfit Patients with CLL
An updated safety and efficacy analysis of the ongoing CLL14 trial showed that venetoclax plus obinutuzumab continues to be an effective treatment for patients with chronic lymphocytic leukemia and coexisting conditions.
Expanded Safety Analysis from CheckMate 648 Shows Tolerability with Frontline Nivolumab Combinations in ESCC
Data from the CheckMate 648 trial informed the FDA’s recent approval of 2 nivolumab combinations for esophageal squamous cell carcinoma. A 1-year follow-up analysis highlighted key safety and time-to-event data surrounding immune-related toxicities.
Biosimilars May Reduce Disparities in Febrile Neutropenia Treatment
At the 2022 Supportive Care in Cancer Annual Meeting, Jeffrey Crawford, MD, highlighted the potential value of biosimilars in reducing gaps in care for the treatment of febrile neutropenia.
Implementation of Individualized Pain Management in Vaso-occlusive Pain Crisis
Utilization of specialty nurse practitioner driven teams and use of individualized pain protocols for patients admitted with vaso-occlusive pain crisis improves quality of life for patients with sickle cell disease, and decreased hospital stay times.
Patients Receiving PD-1/PD-L1 Inhibitor Therapy More Frequently Experience Secondary Adrenal Insufficiency
A study analyzing the long-term adrenal insufficiency outcomes of patients receiving immune checkpoint inhibition therapy found that secondary insufficiency was more common than primary in this patient population.
Does the CDC’s Proposed Opioid Prescribing Guideline Fall Short on Drug Testing?
Although the CDC has put forth a strong effort to improve its opioid guidelines, many providers still feel that more can be done.
Real-World Data Identify Significant Differences in Tolerability Among Approved PARP Inhibitors in Ovarian Cancer
A real-world analysis showed that the proportion of women with ovarian cancer who required dose modifications or treatment discontinuations while receiving PARP inhibitors differed significantly between olaparib, niraparib, and rucaparib.
5-Year Survival Data Showcases Long-Term Benefit With Nivolumab/Ipilimumab-Treated Metastatic NSCLC
Frontline nivolumab and ipilimumab combination therapy was associated with increased 5-year survivorship in patients with metastatic non–small cell lung cancer—regardless of PD-L1 expression.
Frontline Bevacizumab Prolongs PFS, OS in Ovarian Clear Cell Carcinoma
Ovarian clear cell carcinoma is a rare histological type of epithelial ovarian cancer that is typically resistant to chemotherapy and is historically associated with poor prognosis for patients.
Updated PFS Data Continue to Support Nivolumab Plus Relatlimab in Advanced Melanoma
Relatlimab, a human LAG-3 blocking antibody, plus nivolumab, elicited superior progression-free survival in patients with advanced melanoma compared to nivolumab alone.
Vitamin D Insufficiency Predictive of Paclitaxel-Induced Peripheral Neuropathy in Early-Stage Breast Cancer
Patients with early-stage breast cancer who have low vitamin D counts may be at risk of developing chemotherapy-induced peripheral neuropathy.
Patients With HR+/HER2- Advanced Breast Cancer May Reduce Ribociclib Dose Without Jeopardizing Outcomes
Reducing ribociclib dosing by 200 mg or 400 mg did not affect overall survival in patients with hormone receptor–positive, HER2-negative, advanced breast cancer.
Will Requiring the DNP Improve the Quality of Oncology Nursing?
Advocacy and opposition continue to grow regarding the National Organization of Nurse Practitioner Faculties’ goal of requiring the Doctor of Nursing Practice degree (DNP) for entry-level nurse practitioners.
5 Tips for MSNs Looking to Become Nurse Practitioners
Strategic tips for achieving a Nurse Practitioner certification and advancing your nursing career.
Ask The Right Questions: Clinical Pearls of AE Management
In this episode of “The Vitals,” Mark Honor, PA-C, discusses adverse event management in patients receiving different therapeutic options.
New Dosing Guide Will Maximize Buprenorphine Benefit Without Putting Patients at High Risk of Addiction
Experts from Roswell Park developed a dosing guide for the prescription of buprenorphine as treatment for chronic pain.
Shifts in Oncology: Safely Treating Patients in a Post–COVID-19 World
The COVID-19 pandemic has affected oncology practice in many ways. What will safe treating look like moving forward?
Navigating Adverse Events in Oncology Supportive Care
Mark Honor, PA-C, highlights best adverse event management practices for patients undergoing chemotherapy and immune-based treatment.
Bioimpedance Spectroscopy Is a Better Predictor of Chronic Lymphedema Vs Tape Measurement
Patients who underwent surveillance with bioimpedance spectroscopy were less likely to develop chronic breast cancer–related lymphedema compared with patients who were assessed with tape measure.
Geriatric Assessments Help Promote Comorbidity-Related Discussions in Patients With Advanced Cancer
A secondary analysis of the COACH study revealed that a geriatric assessment–guided intervention increased the number of comorbidity-related discussions between patients and providers.
The Value of Nurse Mentorship in Oncology
In this episode of “The Vitals,” 2 veteran oncology nurses discuss the value of mentorship—particularly for novice nurses.
Smoking Cessation Following Lung Cancer Diagnosis Reduces Cancer Mortality Risk
New data support smoking cessation for patients with lung cancer following their diagnosis.
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials
Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer
2 Clarke Drive Cranbury, NJ 08512